Last year as part of CalRx, the State hired Magellan Medicaid to be the new California administrator of Medi-Cal.  Magellan will administer all requests, including SAR requests for factor and non-factor bleeding disorders therapies that are currently approved by GHPP or CCS staff, as of January 1, 2021.
HCC has drafted a one page position paper for state officials in which we are stressing the importance of keeping access to care for GHPP and CCS patients.  At this point in time, HCC recommends continued discussions with DHCS and leaving pharmacy authorizations with CCS and GHPP programs instead of sending those SARs to Magellan Medicaid on January 1, 2021.
You can find the full position paper here.